<DOC>
	<DOCNO>NCT02581462</DOCNO>
	<brief_summary>Previous study provide strong theoretical rationale conduct randomize study evaluate efficacy safety Herceptin pertuzumab combination FLOT perioperative treatment resectable HER-2 positive adenocarcinoma stomach GEJ .</brief_summary>
	<brief_title>FLOT vs. FLOT/Herceptin/Pertuzumab Perioperative Therapy HER-2 Expressing Gastric GEJ Cancer</brief_title>
	<detailed_description>This multicenter , randomize , control , open-label study include patient locally advance adenocarcinoma stomach GEJ schedule receive perioperative chemotherapy . According centrally assess HER-2 status : Patients HER-2 positive tumor receive FLOT +/- Herceptin / pertuzumab . The scope phase II portion trial evaluate pathological response rate either regimen assess centralized pathology define safety tolerability . Patients locally advance esophagogastric adenocarcinoma ( i.e . cT2 N T N-positive ) exclusion distant metastasis include trial . Patients stratified age ( 18-69 vs. ≥ 70 ) , tumor site ( GEJ vs. gastric ) clinical stage ( T1/2 vs. 3/4 N- vs. N+ ) randomize 1:1 receive either FLOT ( Arm A ) FLOT/Herceptin/pertuzumab ( Arm B ) . Arm A ( control group ) Patients randomized Arm A receive 4 pre-operative treatment FLOT ( Docetaxel 50 mg/m² , iv 2 h ; Oxaliplatin 85 mg/m² 500 ml G5 % , iv 2h ; Leucovorin 200 mg/m² 250 ml NaCl 0.9 % , iv 1 h ; 5-FU 2600 mg/m² , iv 24 h ) d1 , d15 , d29 , d43 preoperative treatment phase . Surgery recommend occur 4 week last FLOT ( 4 week d43 = day 71 ) . Patients receive 4 additional post-operative treatment FLOT d1 , d15 , d29 , d43 post-operative treatment phase . Post-operative treatment start 6 8 week , maximum 12 week surgery . Arm B ( Herceptin/pertuzumab group ) Patients randomized Arm B receive FLOT regimen identical Arm A described conjunction three-weekly Herceptin 8mg/kg initial dose ( Day 1 , load dose ) follow subsequent dos Herceptin 6mg/kg d22 d43 pertuzumab 840mg d1 , d22 , d43 . Surgery recommend occur 4 week last FLOT/Herceptin/pertuzumab dose ( 4 week d43 = day 71 ) . Patients receive 3 additional dos Herceptin pertuzumab d1 , d22 , d43 post-operative treatment phase , together postoperative chemotherapy . Moreover , patient receive 11 additional dos Herceptin pertuzumab end post-operative FLOT . In arm , tumor assessment ( CT MRI ) perform randomization prior surgery every 3 month thereafter progression/relapse , death end follow-up . During treatment , clinical visit ( blood cell count , detection toxicity ) occur prior every treatment dose . Safety FLOT/Herceptin/pertuzumab monitor continuously careful monitor adverse event ( AEs ) serious adverse event ( SAEs ) report .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma GEJ ( type IIII ) stomach ( uT2 , uT3 , uT4 , N category , M0 ) , T N+ M0 patient , follow specification : Medical technical operability Centralized detection either adenocarcinoma HER2 3+ ( IHC ) HER2 2+ ( IHC ) amplification proven FISH , SISH CISH 2 . No precede cytotoxic target therapy 3 . No prior partial complete tumor resection 4 . Exclusion infiltration adjacent organ structure CT MRI 5 . Exclusion distant metastasis CT MRI thorax abdomen , bone scan ( osseous lesion suspect due clinical sign ) 6 . Female male patient ≥ 18 year . Patients reproductive age must willing use adequate contraception study 7 month end pertuzumab Herceptin treatment ( Appropriate contraception define surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) ) . Female patient childbearing potential need negative pregnancy test within 7 day study start . 7 . ECOG ≤ 2 8 . Laparoscopic exclusion peritoneal carcinomatosis , suspect clinically 9 . Adequate haematological , hepatic renal function parameter : Leukocytes ≥ 3.000/mm³ , platelet ≥ 100.000/mm3 Serum creatinine ≤ 1.5 x upper limit normal , GFR &gt; 40 ml/min Bilirubin ≤ 1.5 x upper limit normal , AST ALT ≤ 3.5 x upper limit normal , alkaline phosphatase ≤ 6 x upper limit normal 10 . LVEF value &gt; 55 % , assess echocardiography 11 . Patient able willing provide write informed consent comply study protocol plan surgical procedure 1 . Patients involve retroperitoneal ( e.g . paraaortal , paracaval interaortocaval lymph node ) mesenterial lymph node ( distant metastasis ! ) 2 . Known hypersensitivity Herceptin , pertuzumab , 5FU , leucovorin , oxaliplatin , docetaxel 3 . Other known contraindication Herceptin , pertuzumab , 5FU , leucovorin , oxaliplatin , docetaxel 4 . Documented history congestive heart failure NYHA , myocardial infarction within past 6 month first dose study treatment 5 . Clinically significant valvular defect , history poorly control arterial hypertension ( systolic blood pressure &gt; 180 mmHG diastolic blood pressure &gt; 100 mmHg ) uncontrollable highrisk cardiac arrhythmia ( i.e tachycardia heart rate &gt; 100/min rest ) , significant ventricular arrhythmia ( ventricular tachycardia ) high grade atrioventricularblock ( second degree AVblock Type 2 ( Mobitz2 ) third degree AVblock ) 6 . Past current history malignancy curatively treat without evidence disease 5 year , except curatively treat basal cell carcinoma skin situ carcinoma cervix 7 . Known brain metastasis 8 . Other severe internal disease acute infection 9 . Peripheral polyneuropathy ≥ NCI Grade II 10 . Chronic inflammatory bowel disease 11 . Clinically significant active GI bleeding 12 . Ontreatment participation another clinical study period 30 day prior inclusion study 13 . Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . 14 . Patients close institution accord authority court decision ( AMG § 40 , Abs . 1 No . 4 ) 15 . Any concurrent antineoplastic treatment include irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>